Program
XI annual scientific and practical conference of the National Society for the Study of Atherosclerosis (RNAS), dedicated to the 90th anniversary of academician of RAS Yury Petrovich Nikitin
«The problem of atherosclerosis. Perspectives of the 21st century»

14 September 2018, Domina Hotel Novosibirsk, Lenina street, 26, Novosibirsk.

Chairmen
Nikitin YuP (honorary chairman) Kukharchuk VV (vice-chairman)
Voevoda MI (chairman) Ragino YuI (vice-chairman)
Ezhov MV (chairman) Sergienko IV (vice-chairman)

Scientific and Organizational Committee
Ageev FT (Moscow) Kashtalap VV (Kemerovo) Skibitsky VV (Krasnodar)
Arabidze GG (Moscow) Koziolova NA (Perm) Smirnov VN (Moscow)
Aronov DM (Moscow) Konovalov GA (Moscow) Smolenskaya OG
Akhmedzhanov NM Konstantinov VO (St. (Yekaterinburg)
(Moscow) Petersburg) Sokolov AA (St.
Balakhonova TV Kosmacheva ED Petersburg)
(Moscow) (Krasnodar)
Barbarash OL (Kemerovo) Martynov AI (Moscow) Petersburg)
Boytsov SA (Moscow) Metelskaya VA (Moscow) Urvantseva IA (Surgut)
Bubnova MG (Moscow) Meshkov AN (Moscow) Filippov AE (St.
Galavivich AS (Moscow) Obrezen AG (St. (Petersburg)
Gurevich VS (St. Petersburg) Khaisheva LA (Rostov-on-
Petersburg) (Krasnodar)
Drapkina OM (Moscow) Perepech NB (St. Khokhlov RA (Voronezh)
Eregin SYa (Yaroslavl) Petersburg) Chazova IE (Moscow)
Ershova AI (Moscow) Pokrovsky SN (Moscow) Shalnova SA (Moscow)
Zakirova NE (Ufa) Ragino YuI (Novosibirsk) Shaposnik II
Karpov YuA (Moscow) Saifutdinov RI (Orenburg) (Chelyabinsk)
Karpov RS (Tomsk) Samokvalov, EV Yakushin SS (Ryazan)
Kachkovsky MA (Samara) (Krasnoyarsk)

9:00-10:00 Registration.

Plenary session.
Chairpersons: Nikitin YuP (Novosibirsk), Kukharchuk VV (Moscow)

10:00-10:10 Opening. Congratulations to Academician YuP Nikitin

10:10-10:30 Heredity and atherosclerosis: between past and future. Puzyrev VP (Tomsk)

10:30-10:50 The role of modern imaging technologies in early diagnosis and assessment of atherosclerosis severity. Karpov RS, Boshchenko AA, Vrublevsky AV, Pavlyukova EN, Usov YYu, Zavadovsky KV (Tomsk)

10:50-11:10 Atherosclerosis and metabolic syndrome in Siberia. Voevoda MI (Novosibirsk)

11:10-11:30 Regional fat depots: fundamental and practical aspects in cardiology. Barbarash OL (Kemerovo)

11:30-12:10 Lunch break
<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1</th>
<th>Room 2</th>
</tr>
</thead>
</table>
| 12:10-13:40     | Scientific Symposium *"Diagnostic and clinical aspects of atherosclerosis"*  
*Chairpersons:* Gurevich VS (St. Petersburg); Malyutina SK (Novosibirsk)  
1. Actual aspects of diagnosis and treatment of familial hypercholesterolemia. Konstantinov VO (St. Petersburg)  
2. Age trajectories of blood lipid levels: long-term observation in the population. Malyutina SK (Novosibirsk)  
4. Features of early atherosclerosis in women with rheumatoid arthritis. Osipova IV (Barnaul)  
5. Ultrasonic phenotyping in studies of subclinical atherosclerosis. Ryabikov AN (Novosibirsk)  
6. Atherosclerosis of the coronary arteries in the population of Yakutia: ethnic and gender characteristics. Romanova AN (Yakutsk)  |
*Chairpersons:* Bubnova MG (Moscow), Sergienko IV (Moscow)  
1. Cardiovascular catastrophes and modern target levels of lipids. Bubnova MG (Moscow)  
2. Diets and other non-drug methods in the treatment of dyslipidemia. Akhmedzhanov NM (Moscow)  
3. Glucose and atherosclerosis. Sergienko IV (Moscow)  |
| 13:40-14:00     |                                                                                                                 | *Recordati Symposium *"Statin therapy in real clinical practice"*  
*Chairpersons:* Aronov DM (Moscow), Kukharchuk VV (Moscow)  
1. Lipid-lowering therapy 2018. Lansberg P (Netherlands)  
2. How to achieve the goal in primary and secondary prevention: new goals of LDL-C. Gurevich VS (St. Petersburg)  
3. Hypolipidemic therapy: real clinical practice - optimal solution. Bubnova MG (Moscow)  |
| 14:00-15:30     | Scientific Symposium *"Hyperlipidemia and treatment of atherosclerosis"*  
*Chairpersons:* Pokrovsky SN (Moscow), Sokolov AA (St. Petersburg)  
1. The frequency of severe hypercholesterolemia in patients with acute coronary syndrome. Data from the Russian register of acute coronary syndrome. Ezhov MV (Moscow)  
2. Therapeutic apheresis in the treatment of cardiovascular diseases. Pokrovsky SN (Moscow)  
3. The problem of in-stent restenosis. The possibility of therapeutic apheresis. Tishko VV, Sokolov AA, Belskykh AN (St. Petersburg)  
4. Lipid-lowering therapy in patients at high cardiovascular risk. Sergienko IV (Moscow)  
5. Innovative clinical and organizational technologies of specialized medical care for patients with severe lipid metabolism disorders. Experience of Kemerovo Lipid Center. Kashtalap VV, Pecherina TB, |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-15:45</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>15:45-17:15</td>
<td><strong>Scientific Symposium &quot;Genetics and biochemistry of atherosclerosis&quot;</strong>&lt;br&gt;<strong>Chairpersons:</strong> Metelskaya VA (Moscow), Ragino YuI (Novosibirsk)&lt;br&gt;1. The main achievements on the way from the lipid clinic to new atherosclerosis biomarkers. Metelskaya VA (Moscow)&lt;br&gt;2. Genetics of atherosclerosis - the role of rare mutations. Meshkov AN (Moscow)&lt;br&gt;3. Features of the transcriptome profile of unstable atherosclerotic plaques. Shakhtshneider, EV, Ivanoschuk DE, Ragino YI, Voevoda MI (Novosibirsk)&lt;br&gt;4. Biochemical markers of the probability of unstable plaques in the coronary arteries. Ragino YuI (Novosibirsk)&lt;br&gt;5. The importance of confrontation between hemostatic and fibrinolytic reactions in the development of vascular ischemia. Momot AP (Barnaul)&lt;br&gt;6. Approbation of modern atherosclerosis markers. Vorobyova EN (Barnaul)&lt;br&gt;* Sanofi Symposium: &quot;Monitoring of low-density lipoprotein cholesterol as a leading factor in improving prognosis in patients after myocardial infarction: time for practical solutions&quot;**&lt;br&gt;<strong>Chairpersons:</strong> Voevoda MI (Novosibirsk)&lt;br&gt;1. What should be the lipid-lowering therapy in patients after myocardial infarction in light of the recent studies results? Ezhov MV (Moscow)&lt;br&gt;2. New goals of dyslipidemia correction in diabetes combined with atherosclerosis – is it a distant prospect or reality? Barbarash OL (Kemerovo)&lt;br&gt;3. PCSK9 inhibitors in patients with myocardial infarction: how to reproduce the results of studies in clinical practice? Gurevich VS (St. Petersburg)</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>
lower extremities. Karpenko AA (Novosibirsk)

| 19:00-20:00 | Dinner |

* The Symposium is held with the support of a pharmaceutical company, CME credit points are not awarded